Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
702.9 INR | +1.66% | +4.47% | +4.03% |
Feb. 06 | Vijaya Diagnostic Centre's Consolidated Profit Jumps in Fiscal Q3 | MT |
Feb. 06 | Transcript : Vijaya Diagnostic Centre Limited, Q3 2024 Earnings Call, Feb 06, 2024 |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- The opinion of analysts covering the stock has improved over the past four months.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- With an expected P/E ratio at 60.95 and 49.04 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+4.03% | 863M | B- | ||
-17.89% | 8.25B | B+ | ||
+39.20% | 3.58B | C+ | ||
-39.11% | 2.46B | B- | ||
-8.06% | 2.46B | - | ||
-7.35% | 2.38B | B- | ||
-19.01% | 1.55B | A- | ||
-40.66% | 1.21B | C+ | ||
+7.56% | 1.11B | B+ | ||
-15.34% | 1.03B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- VIJAYA Stock
- Ratings Vijaya Diagnostic Centre Limited